Antibody-drug conjugates are reshaping the HER2-low breast cancer setting
T-DXd's expansion into HER2-low has changed second-line decision-making, and the ADC class is delivering further candidates that are likely to redefine biomarker-driven sequencing across breast cancer subtypes.
The ADC class has moved from a niche option to the modal next-line therapy in HER2-low metastatic breast cancer over the past two years. Trastuzumab deruxtecan's expanded labeling repositioned the boundary between HER2-zero and HER2-low - a distinction that has practical consequences for assay choice, lab workflow, and prescribing.
What is happening downstream is more interesting. Several follow-on ADCs targeting different antigens (TROP2, HER3, FRalpha) are reading out in the same setting and the field is now negotiating sequencing rather than positioning a single agent. Real-world toxicity management - particularly interstitial lung disease surveillance - is the operational story underneath the efficacy story.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.